{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T16:43:21Z","timestamp":1772556201558,"version":"3.50.1"},"reference-count":87,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Pancreatic neuroendocrine tumors (pNETs) are rare, clinically heterogeneous neoplasms with rising incidence linked to improved diagnostics. This review examines pNET management, addressing epidemiology, classification, diagnosis, treatment, and emerging therapies. Epidemiologically, pNETs show higher prevalence in Western populations, with emerging associations to metabolic disorders. The 2022 WHO classification highlights distinct prognoses for well-differentiated NETs versus poorly differentiated NECs, guided by Ki-67 and mitotic indices. Non-functional tumors often present late, while functional variants manifest hormonal syndromes, necessitating tailored approaches. Advanced imaging (contrast-enhanced CT\/MRI, 68Ga-DOTATATE PET) and endoscopic ultrasound-guided biopsy enable precise localization and grading. Surgical resection remains curative for localized disease, with minimally invasive techniques reducing morbidity. Active surveillance is favored for small (&lt;2 cm), low-grade, non-functional tumors, while larger or aggressive lesions require resection. Systemic therapies, including mTOR inhibitors (everolimus), anti-angiogenics (surufatinib), and peptide receptor radionuclide therapy (PRRT), extend survival in advanced cases, though immunotherapy efficacy remains limited. Future strategies emphasize molecular profiling, biomarker development, and multidisciplinary integration to optimize outcomes. This evolving paradigm prioritizes precision medicine, balancing oncologic control with quality of life and functional preservation.<\/jats:p>","DOI":"10.3390\/medicina62030479","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T12:48:56Z","timestamp":1772542136000},"page":"479","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pancreatic Neuroendocrine Tumors: From Benchside to Surgical Treatment"],"prefix":"10.3390","volume":"62","author":[{"given":"Giovanni","family":"Conzo","sequence":"first","affiliation":[{"name":"Division of General, Oncological, Mini-Invasive and Obesity Surgery, University of Study of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4980-0335","authenticated-orcid":false,"given":"Federico Maria","family":"Mongardini","sequence":"additional","affiliation":[{"name":"Division of General, Oncological, Mini-Invasive and Obesity Surgery, University of Study of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5057-1981","authenticated-orcid":false,"given":"Maddalena","family":"Paolicelli","sequence":"additional","affiliation":[{"name":"Division of General, Oncological, Mini-Invasive and Obesity Surgery, University of Study of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9505-7306","authenticated-orcid":false,"given":"Michele","family":"Klain","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples \u201cFederico II\u201d, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4748-321X","authenticated-orcid":false,"given":"Giuseppe","family":"Bellastella","sequence":"additional","affiliation":[{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Conzo","sequence":"additional","affiliation":[{"name":"Division of General, Oncological, Mini-Invasive and Obesity Surgery, University of Study of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhou","family":"Bo","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Lanza","sequence":"additional","affiliation":[{"name":"Division of General, Oncological, Mini-Invasive and Obesity Surgery, University of Study of Campania \u201cLuigi Vanvitelli\u201d, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5487-1360","authenticated-orcid":false,"given":"Leandra","family":"Piscopo","sequence":"additional","affiliation":[{"name":"Radiology Department of Surgery, Medicine and Pharmacy, University of Sassari, 07100 Sassari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6969-4157","authenticated-orcid":false,"given":"Renato","family":"Patrone","sequence":"additional","affiliation":[{"name":"Hepatobiliary Surgical Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale-IRCCS di Napoli, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s12020-023-03515-3","article-title":"Preoperative prediction of pancreatic neuroendocrine tumor grade based on 68Ga-DOTATATE PET\/CT","volume":"83","author":"Ma","year":"2024","journal-title":"Endocrine"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/archsurg.142.4.347","article-title":"Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: The Massachusetts General Hospital experience from 1977 to 2005","volume":"142","author":"Vagefi","year":"2007","journal-title":"Arch. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Souche, R., Hobeika, C., Hain, E., and Gaujoux, S. (2020). Surgical Management of Neuroendocrine Tumours of the Pancreas. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092993"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000443171","article-title":"ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors","volume":"103","author":"Falconi","year":"2016","journal-title":"Neuroendocrinology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"105878","DOI":"10.1016\/j.esmoop.2025.105878","article-title":"Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET)","volume":"10","author":"Spada","year":"2025","journal-title":"ESMO Open"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/MPA.0000000000000110","article-title":"A systematic review of localization, surgical treatment options, and outcome of insulinoma","volume":"43","author":"Mehrabi","year":"2014","journal-title":"Pancreas"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.3748\/wjg.v26.i19.2305","article-title":"Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management","volume":"26","author":"Ma","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","article-title":"Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?","volume":"23","author":"Das","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"103572","DOI":"10.1016\/j.critrevonc.2021.103572","article-title":"Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)\/Italian Association of Medical Diabetologists (AMD)\/Italian Society of Endocrinology (SIE)\/Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper","volume":"169","author":"Natalicchio","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000443172","article-title":"ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas","volume":"103","author":"Sorbye","year":"2016","journal-title":"Neuroendocrinology"},{"key":"ref_12","first-page":"35","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: Current development, challenges, and clinical perspectives","volume":"11","author":"Zhang","year":"2024","journal-title":"Mil. Med. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"548","DOI":"10.21037\/jgo.2020.03.07","article-title":"Pancreatic neuroendocrine neoplasms: Current state and ongoing controversies on terminology, classification and prognostication","volume":"11","author":"Taskin","year":"2020","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e22291","DOI":"10.1097\/MD.0000000000022291","article-title":"A comprehensive validation of the novel 8th edition of American Joint Committee on Cancer staging manual for the long-term survivals of patients with non-functional pancreatic neuroendocrine neoplasms","volume":"99","author":"Yang","year":"2020","journal-title":"Medicine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.suc.2019.04.014","article-title":"Evaluation and Management of Neuroendocrine Tumors of the Pancreas","volume":"99","author":"Scott","year":"2019","journal-title":"Surg. Clin. N. Am."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1093\/annonc\/mdn351","article-title":"Pancreatic neuroendocrine tumors (PNETs): Incidence, prognosis and recent trend toward improved survival","volume":"19","author":"Halfdanarson","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1053\/j.gastro.2008.05.047","article-title":"Gastrointestinal neuroendocrine tumors: Pancreatic endocrine tumors","volume":"135","author":"Metz","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00535-016-1250-9","article-title":"Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan","volume":"52","author":"Ito","year":"2017","journal-title":"J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Patrone, R., Mongardini, F.M., Conzo, A., Cacciatore, C., Cozzolino, G., Catauro, A., Lanza, E., Izzo, F., Belli, A., and Palaia, R. (2024). Pancreatic Neuroendocrine Tumors: What Is the Best Surgical Option?. J. Clin. Med., 13.","DOI":"10.20944\/preprints202404.0692.v1"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1245\/s10434-014-4145-0","article-title":"Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group","volume":"22","author":"Singh","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.soc.2015.12.003","article-title":"Clinical Presentation and Diagnosis of Pancreatic Neuroendocrine Tumors","volume":"25","author":"Anderson","year":"2016","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.amjsurg.2015.08.012","article-title":"Clinical presentation and outcome of nonfunctional pancreatic neuroendocrine tumors in a modern cohort","volume":"210","author":"Watley","year":"2015","journal-title":"Am. J. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/SLA.0000000000005941","article-title":"Early-Onset Pancreatic Neuroendocrine Tumors: Clinical Presentation, Pathology Features, and Oncological Outcomes","volume":"279","author":"Pulvirenti","year":"2024","journal-title":"Ann. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/bjc.2012.560","article-title":"Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours","volume":"108","author":"Yadegarfar","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ejca.2005.10.025","article-title":"Development of a disease-specific Quality of Life questionnaire module for patients with gastrointestinal neuroendocrine tumours","volume":"42","author":"Davies","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"van Leeuwaarde, R.S., Gonz\u00e1lez-Clavijo, A.M., Pracht, M., Emelianova, G., Cheung, W.Y., Thirlwell, C., \u00d6berg, K., and Spada, F. (2022). A Multinational Pilot Study on Patients\u2019 Perceptions of Advanced Neuroendocrine Neoplasms on the EORTC QLQ-C30 and EORTC QLQ-GINET21 Questionnaires. J. Clin. Med., 11.","DOI":"10.3390\/jcm11051271"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12955-021-01688-x","article-title":"Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: A multicentre, cross-sectional survey (QUALINETS)","volume":"19","author":"Benavent","year":"2021","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.3748\/wjg.v26.i25.3686","article-title":"Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review","volume":"26","author":"Watson","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"9512","DOI":"10.3748\/wjg.v21.i32.9512","article-title":"Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management","volume":"21","author":"Cloyd","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/0284185115579932","article-title":"Diagnostic imaging of pancreatic neuroendocrine neoplasms (pNEN): Tumor detection, staging, prognosis, and response to treatment","volume":"57","author":"Baur","year":"2016","journal-title":"Acta Radiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8118","DOI":"10.3748\/wjg.v21.i26.8118","article-title":"Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading","volume":"21","author":"Sugimoto","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1177\/2050640616680972","article-title":"Endoscopic ultrasound-guided fine needle aspiration of pancreatic lesions with 22 versus 25 Gauge needles: A meta-analysis","volume":"5","author":"Facciorusso","year":"2017","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1055\/a-2524-2596","article-title":"Endoscopic ultrasound-guided tissue sampling: European Society of Gastrointestinal Endoscopy (ESGE) Technical and Technology Review","volume":"57","author":"Facciorusso","year":"2025","journal-title":"Endoscopy"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/cyt.12111","article-title":"Pancreatic neuroendocrine tumour grading on endoscopic ultrasound-guided fine needle aspiration: High reproducibility and inter-observer agreement of the Ki-67 labelling index","volume":"25","author":"Weynand","year":"2014","journal-title":"Cytopathology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000477213","article-title":"Accuracy of Pancreatic Neuroendocrine Tumour Grading by Endoscopic Ultrasound-Guided Fine Needle Aspiration: Analysis of a Large Cohort and Perspectives for Improvement","volume":"106","author":"Boutsen","year":"2018","journal-title":"Neuroendocrinology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"E398","DOI":"10.1503\/cmaj.160771","article-title":"Principles of diagnosis and management of neuroendocrine tumours","volume":"189","author":"Raphael","year":"2017","journal-title":"CMAJ"},{"key":"ref_38","first-page":"358","article-title":"Novel agents in the treatment of unresectable neuroendocrine tumors","volume":"12","author":"Oberstein","year":"2011","journal-title":"JOP J. Pancreas"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Armellini, E., Facciorusso, A., and Crin\u00f2, S.F. (2023). Efficacy and Safety of Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Neuroendocrine Tumors: A Systematic Review and Metanalysis. Medicina, 59.","DOI":"10.3390\/medicina59020359"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MPA.0000000000001454","article-title":"The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors","volume":"49","author":"Howe","year":"2020","journal-title":"Pancreas"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1016\/j.ijsu.2015.12.052","article-title":"Pancreatic neuroendocrine tumors: Nosography, management and treatment","volume":"28","author":"Orditura","year":"2016","journal-title":"Int. J. Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ijsu.2015.04.089","article-title":"Conservative management and parenchyma-sparing resections of pancreatic neuroendocrine tumors: Literature review","volume":"21","author":"Mauriello","year":"2015","journal-title":"Int. J. Surg."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.3892\/ijo.2016.3711","article-title":"Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET)","volume":"49","author":"Jin","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.soc.2019.11.008","article-title":"Surgical Management of Pancreatic Neuroendocrine Tumors","volume":"29","author":"Vaghaiwalla","year":"2020","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00595-019-01838-1","article-title":"Indications for resection and perioperative outcomes of surgery for pancreatic neuroendocrine neoplasms in Germany: An analysis of the prospective DGAV StuDoQ|Pancreas registry","volume":"49","author":"Mintziras","year":"2019","journal-title":"Surg. Today"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejso.2018.08.016","article-title":"Exploring the surgical landscape of pancreatic neuroendocrine neoplasia in Austria: Results from the ASSO pNEN study group","volume":"45","author":"Primavesi","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"13893","DOI":"10.3748\/wjg.v20.i38.13893","article-title":"Update on surgical treatment of pancreatic neuroendocrine neoplasms","volume":"20","author":"Tosolini","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1245\/s10434-020-08850-7","article-title":"Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors","volume":"28","author":"Tanaka","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.eprac.2024.07.010","article-title":"Management of Pancreatic Neuroendocrine Tumors: Surgical Strategies and Controversies","volume":"30","author":"Perry","year":"2024","journal-title":"Endocr. Pract."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/17474124.2017.1253473","article-title":"Systematic review and meta-analysis on laparoscopic pancreatic resections for neuroendocrine neoplasms (PNENs)","volume":"11","author":"Tamburrino","year":"2017","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/hpb.12162","article-title":"Laparoscopic versus open pancreas resection for pancreatic neuroendocrine tumours: A systematic review and meta-analysis","volume":"16","author":"Drymousis","year":"2014","journal-title":"HPB"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1007\/s00464-020-07639-9","article-title":"Robotic-assisted versus open distal pancreatectomy for benign and low-grade malignant pancreatic tumors: A propensity score-matched study","volume":"35","author":"Weng","year":"2021","journal-title":"Surg. Endosc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1007\/s00268-020-05707-8","article-title":"Short- and long-term outcomes of laparoscopic organ-sparing resection for pancreatic neuroendocrine neoplasms","volume":"44","author":"Zhang","year":"2020","journal-title":"World J. Surg."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/gs.2017.10.06","article-title":"Surgical resection of pancreatic neuroendocrine neoplasm by minimally invasive surgery-the robotic approach?","volume":"7","author":"Teo","year":"2018","journal-title":"Gland Surg."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1007\/s00464-018-6576-3","article-title":"Robotic enucleations of pancreatic benign or low-grade malignant tumors: Preliminary results and comparison with robotic demolitive resections","volume":"33","author":"Bartolini","year":"2019","journal-title":"Surg. Endosc."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Sulciner, M.L., and Clancy, T.E. (2023). Surgical Management of Pancreatic Neuroendocrine Tumors. Cancers, 15.","DOI":"10.3390\/cancers15072006"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1345\/aph.1R087","article-title":"Everolimus: A new treatment option for advanced pancreatic neuroendocrine tumors","volume":"46","author":"Thompson","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000100057","article-title":"The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells","volume":"85","author":"Zitzmann","year":"2007","journal-title":"Neuroendocrinology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1159\/000505550","article-title":"A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial)","volume":"110","author":"Okuyama","year":"2020","journal-title":"Neuroendocrinology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2217\/cer-2018-0020","article-title":"Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: An updated matching-adjusted indirect comparison","volume":"7","author":"Ishak","year":"2018","journal-title":"J. Comp. Eff. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","article-title":"Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): A randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"17588359211042689","DOI":"10.1177\/17588359211042689","article-title":"Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs)","volume":"13","author":"Xu","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/RLU.0000000000005330","article-title":"177 Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Data from the Prospective Phase 2 LUMEN Study","volume":"49","author":"Mileva","year":"2024","journal-title":"Clin. Nucl. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.3390\/curroncol31090416","article-title":"The Safety and Efficacy of Peptide Receptor Radionuclide Therapy for Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Single Center Experience","volume":"31","author":"Piscopo","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1007\/s00259-021-05236-z","article-title":"Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors","volume":"48","author":"Nicolini","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/jhbp.1101","article-title":"Safety and response after peptide receptor radionuclide therapy with 177Lu-DOTATATE for neuroendocrine tumors in phase 1\/2 prospective Japanese trial","volume":"29","author":"Kudo","year":"2022","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3390\/curroncol28010015","article-title":"Efficacy of 177Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study","volume":"28","author":"Sistani","year":"2020","journal-title":"Curr. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Harris, P.E., and Zhernosekov, K. (2022). The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.941832"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Kolodziej, M., Opalinska, M., Mikolajczak, R., Hubalewska-Dydejczyk, A., Dedecjus, M., Kowalska, A., Saracyn, M., Garnuszek, P., Cieszykowska, I., and Januszkiewicz-Caulier, J. (2025). Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: Interim safety analysis of the DUONEN trial. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1716247"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Ngongoni, R., and Visser, B. (2022). Surgery, Liver Directed Therapy and Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumor Liver Metastases. Cancers, 14.","DOI":"10.3390\/cancers14205103"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40792-024-01839-4","article-title":"Pathological complete response of initially unresectable multiple liver metastases achieved using combined peptide receptor radionuclide therapy and somatostatin analogs following pancreatic neuroendocrine tumor resection: A case report","volume":"10","author":"Umino","year":"2024","journal-title":"Surg. Case Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2169\/internalmedicine.3768-24","article-title":"Grade 3 Pancreatic Neuroendocrine Tumor Refractory to Chemotherapy Successfully Treated with Peptide Receptor Radionuclide Therapy Leading to Conversion Surgery","volume":"64","author":"Sakaki","year":"2025","journal-title":"Intern. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1002\/cncr.32883","article-title":"Pembrolizumab for the treatment of programmed death\u2013ligand 1\u2013positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study","volume":"126","author":"Mehnert","year":"2020","journal-title":"Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1158\/1078-0432.CCR-19-3014","article-title":"Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results from the Phase II KEYNOTE-158 Study","volume":"26","author":"Strosberg","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1158\/1078-0432.CCR-20-0621","article-title":"Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers","volume":"26","author":"Klein","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e625","DOI":"10.1093\/oncolo\/oyac097","article-title":"Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms","volume":"27","author":"Jia","year":"2022","journal-title":"Oncologist"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1001\/jamaoncol.2022.0212","article-title":"Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients with Neuroendocrine Tumors: A Nonrandomized Clinical Trial","volume":"8","author":"Halperin","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2217\/fon-2020-0703","article-title":"Immunotherapy and potential predictive biomarkers in the treatment of neuroendocrine neoplasia","volume":"17","author":"Xu","year":"2021","journal-title":"Future Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Ungefroren, H., K\u00fcnstner, A., Busch, H., Franzenburg, S., Luley, K., Viol, F., Schrader, J., Konukiewitz, B., Wellner, U.F., and Meyh\u00f6fer, S.M. (2022). Differential Effects of Somatostatin, Octreotide, and Lanreotide on Neuroendocrine Differentiation and Proliferation in Established and Primary NET Cell Lines: Possible Crosstalk with TGF-\u03b2 Signaling. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415868"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1023\/A:1008205415035","article-title":"High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects","volume":"8","author":"Eriksson","year":"1997","journal-title":"Ann. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000519605","article-title":"Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors","volume":"100","author":"Allaw","year":"2022","journal-title":"Oncology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e643","DOI":"10.1093\/oncolo\/oyad325","article-title":"Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study","volume":"29","author":"Pavel","year":"2024","journal-title":"Oncologist"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e13496","DOI":"10.1111\/jne.13496","article-title":"Phase Ib\/II study of Pembrolizumab with Lanreotide depot for advanced, progressive Gastroenteropancreatic neuroendocrine tumors (PLANET)","volume":"37","author":"Morse","year":"2025","journal-title":"J. Neuroendocrinol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1007\/s00259-022-05792-y","article-title":"In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy","volume":"49","author":"Ledwon","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1007\/s00259-025-07351-7","article-title":"Novel framework for response evaluation criteria in grade 1\/2 neuroendocrine tumors (RECIN) following [177Lu]Lu-DOTATATE therapy: Post-hoc analysis of the phase 2 LuCAP trial","volume":"52","author":"Satapathy","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/3\/479\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T14:23:28Z","timestamp":1772547808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/3\/479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":87,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["medicina62030479"],"URL":"https:\/\/doi.org\/10.3390\/medicina62030479","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]}}}